DE60026998D1 - Screeningsverfahren zur änderung zirkadiane-rhythmus-eiweisse - Google Patents
Screeningsverfahren zur änderung zirkadiane-rhythmus-eiweisseInfo
- Publication number
- DE60026998D1 DE60026998D1 DE60026998T DE60026998T DE60026998D1 DE 60026998 D1 DE60026998 D1 DE 60026998D1 DE 60026998 T DE60026998 T DE 60026998T DE 60026998 T DE60026998 T DE 60026998T DE 60026998 D1 DE60026998 D1 DE 60026998D1
- Authority
- DE
- Germany
- Prior art keywords
- alter
- ability
- directed
- phosphorylation
- circadian rhythm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32774599A | 1999-06-08 | 1999-06-08 | |
| US327745 | 1999-06-08 | ||
| PCT/US2000/015633 WO2000075669A1 (en) | 1999-06-08 | 2000-06-07 | Screening methods for altering circadian rhythm proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60026998D1 true DE60026998D1 (de) | 2006-05-18 |
| DE60026998T2 DE60026998T2 (de) | 2007-04-05 |
Family
ID=23277866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60026998T Expired - Lifetime DE60026998T2 (de) | 1999-06-08 | 2000-06-07 | Screeningsverfahren zur änderung zirkadiane-rhythmus-eiweisse |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6555328B1 (de) |
| EP (1) | EP1183541B1 (de) |
| JP (1) | JP4583682B2 (de) |
| KR (1) | KR100722176B1 (de) |
| AT (1) | ATE322016T1 (de) |
| AU (1) | AU767800B2 (de) |
| BR (1) | BR0011437A (de) |
| CA (1) | CA2375450C (de) |
| DE (1) | DE60026998T2 (de) |
| IL (2) | IL146729A0 (de) |
| MX (1) | MXPA01011417A (de) |
| NO (3) | NO330241B1 (de) |
| NZ (1) | NZ514603A (de) |
| WO (1) | WO2000075669A1 (de) |
| ZA (1) | ZA200108962B (de) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6436628B1 (en) | 1998-06-19 | 2002-08-20 | The Rockefeller University | Methods of identifying an agent which modulates period and doubletime protein interaction |
| US6476188B1 (en) | 1998-06-19 | 2002-11-05 | The Rockefeller University | Clock gene and methods of use thereof |
| WO2000075669A1 (en) * | 1999-06-08 | 2000-12-14 | Aventis Pharmaceuticals Inc. | Screening methods for altering circadian rhythm proteins |
| JP4262921B2 (ja) * | 1999-11-18 | 2009-05-13 | 田辺三菱製薬株式会社 | リズムを有する発現をもたらすＰｅｒｉｏｄ１プロモーターが導入されたトランスジェニック哺乳動物 |
| GB0103110D0 (en) * | 2000-08-25 | 2001-03-28 | Aventis Pharma Inc | A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1 |
| WO2002055667A2 (en) * | 2001-01-11 | 2002-07-18 | Univ Utah Res Found | Identification of an advanced sleep phase syndrome gene in humans |
| WO2004038043A2 (en) * | 2002-10-25 | 2004-05-06 | University Of Surrey | POLYMORPHISM IN THE Per3 GENE AS A INDICATOR IN THE DIAGNOSIS AND TREATMENT OF CIRCADIAN RHYTHM SLEEP DISORDERS |
| US20060134619A1 (en) * | 2002-11-27 | 2006-06-22 | Louis Ptacek | Casein kinase i epsilon and casein kinase i delta and sleep in humans |
| JO2629B1 (en) | 2004-08-19 | 2012-06-24 | افينتيس فارما سوتيكالز انك | Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon |
| JO2724B1 (en) * | 2004-08-19 | 2013-09-15 | افينتس فارماسوتيكالز انك | 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors |
| PL1791537T3 (pl) * | 2004-08-19 | 2010-04-30 | Aventis Pharma Inc | Pochodne 3-arylotioindolo-2-karboksamidów i ich analogi jako inhibitory kinazy kazeinowej I |
| JP2009538597A (ja) * | 2006-05-31 | 2009-11-12 | 独立行政法人放射線医学総合研究所 | 光誘導性周期的発現遺伝子及び体内時計システムに影響を与える物質のスクリーニング方法 |
| ES2425179T3 (es) * | 2006-10-25 | 2013-10-11 | The Rockefeller University | Métodos para el tratamiento de trastornos relacionados con beta-amiloide y composiciones para los mismos |
| FR2918986B1 (fr) | 2007-07-19 | 2009-09-04 | Sanofi Aventis Sa | Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique |
| WO2015054819A1 (en) * | 2013-10-14 | 2015-04-23 | Nanjing University | Method for identifying advanced feeding rhythm syndrome and application thereof |
| KR101600144B1 (ko) * | 2013-12-20 | 2016-03-04 | 서울대학교산학협력단 | 일주기 리듬 수면장애 및 시차 부적응에 대한 예방 또는 치료제 스크리닝 방법 |
| MX2016008968A (es) | 2014-01-09 | 2016-10-26 | Intra-Cellular Therapies Inc | Compuestos organicos. |
| WO2017083835A1 (en) * | 2015-11-13 | 2017-05-18 | The Trustees Of Columbia University In The City Of New York | Inhibition of tor complex 2 increases immunity against bacterial infection |
| WO2023129377A1 (en) * | 2022-01-03 | 2023-07-06 | The Johns Hopkins University | Methods and materials for treating heart attack |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1157137A (ja) * | 1997-08-28 | 1999-03-02 | Sanyo Bussan Kk | 遊技機用特別図柄表示装置 |
| KR100246893B1 (ko) * | 1997-12-29 | 2000-05-01 | 윤종용 | 전자렌지용 도어 |
| AU3976099A (en) * | 1998-05-07 | 1999-11-23 | President & Fellows Of Harvard College, The | Compositions and methods involving regulation of mammalian circadian rhythms |
| WO2000075669A1 (en) * | 1999-06-08 | 2000-12-14 | Aventis Pharmaceuticals Inc. | Screening methods for altering circadian rhythm proteins |
-
2000
- 2000-06-07 WO PCT/US2000/015633 patent/WO2000075669A1/en active IP Right Grant
- 2000-06-07 MX MXPA01011417A patent/MXPA01011417A/es active IP Right Grant
- 2000-06-07 JP JP2001501893A patent/JP4583682B2/ja not_active Expired - Fee Related
- 2000-06-07 AT AT00939629T patent/ATE322016T1/de active
- 2000-06-07 DE DE60026998T patent/DE60026998T2/de not_active Expired - Lifetime
- 2000-06-07 KR KR1020017015764A patent/KR100722176B1/ko not_active IP Right Cessation
- 2000-06-07 BR BR0011437-5A patent/BR0011437A/pt not_active Application Discontinuation
- 2000-06-07 IL IL14672900A patent/IL146729A0/xx active IP Right Grant
- 2000-06-07 CA CA002375450A patent/CA2375450C/en not_active Expired - Fee Related
- 2000-06-07 US US09/589,462 patent/US6555328B1/en not_active Expired - Lifetime
- 2000-06-07 AU AU54689/00A patent/AU767800B2/en not_active Ceased
- 2000-06-07 NZ NZ514603A patent/NZ514603A/en not_active IP Right Cessation
- 2000-06-07 EP EP00939629A patent/EP1183541B1/de not_active Expired - Lifetime
-
2001
- 2001-10-30 ZA ZA200108962A patent/ZA200108962B/en unknown
- 2001-11-25 IL IL146729A patent/IL146729A/en not_active IP Right Cessation
- 2001-12-06 NO NO20015972A patent/NO330241B1/no not_active IP Right Cessation
-
2010
- 2010-03-23 NO NO20100430A patent/NO20100430L/no not_active Application Discontinuation
- 2010-03-23 NO NO20100431A patent/NO20100431L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20015972D0 (no) | 2001-12-06 |
| IL146729A (en) | 2007-06-17 |
| CA2375450A1 (en) | 2000-12-14 |
| NO20100431L (no) | 2002-02-05 |
| WO2000075669A1 (en) | 2000-12-14 |
| KR20020033101A (ko) | 2002-05-04 |
| MXPA01011417A (es) | 2002-06-04 |
| CA2375450C (en) | 2009-04-28 |
| EP1183541B1 (de) | 2006-03-29 |
| JP2003501074A (ja) | 2003-01-14 |
| JP4583682B2 (ja) | 2010-11-17 |
| NO20100430L (no) | 2002-02-05 |
| BR0011437A (pt) | 2002-03-05 |
| NO330241B1 (no) | 2011-03-14 |
| NO20015972L (no) | 2002-02-05 |
| KR100722176B1 (ko) | 2007-05-29 |
| DE60026998T2 (de) | 2007-04-05 |
| ATE322016T1 (de) | 2006-04-15 |
| AU767800B2 (en) | 2003-11-27 |
| IL146729A0 (en) | 2002-07-25 |
| US6555328B1 (en) | 2003-04-29 |
| AU5468900A (en) | 2000-12-28 |
| ZA200108962B (en) | 2003-01-30 |
| EP1183541A1 (de) | 2002-03-06 |
| NZ514603A (en) | 2003-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20100431L (no) | Fremgangsmate for a endre degradering av det humane klokkeproteinet hPeriode1 (hPER1) | |
| CY1108655T1 (el) | ΘΕΙΟΖΟΛΙΔΙΝ-4-ΟΝΕΣ ΓΙΑ ΤΗΝ ΑΝΑΣΤΟΛΗ ΠΡΩΤΕΪΝΩΝ hYAK3 | |
| ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
| DE69918549D1 (de) | Gerät zur feststellung von zahnbelag mittels fluoreszenzmessung | |
| DE69903898T2 (de) | Teststreifen zur visuellen Ermittlung der Blutglukose-Konzentration | |
| ATE269303T1 (de) | Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen | |
| ATE425965T1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
| DE69938662D1 (de) | Spurendetektion von analyten mit hilfe artifizieller olfaktometrie | |
| BR0111125A (pt) | Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos | |
| DE60026452D1 (de) | Verfahren zur Identifizierung von Peptidensequenzen und Proteinensequenzen mittels Massenspektromterie | |
| DE69821667D1 (de) | Kardioverter zur Behandlung von Vorhofflattern | |
| DE60032795D1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
| ATE527022T1 (de) | Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie | |
| DE69827126D1 (de) | Verwendung von hypothalamus-hemmfaktor zur behandlung von ischämischen herzstörungen | |
| DE69739026D1 (de) | Nitril-Hydratase, ihre Derivate und Verfahren zur Herstellung von Verbindungen | |
| DE60104810D1 (de) | Zellfreies Verfahren zur Herstellung von posttranslational veränderten Proteinen | |
| DE60130661D1 (de) | Verwendung der 13-cis retinsäure zur behandlung von emphysemen | |
| DE69621799D1 (de) | Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen | |
| DE69326018T2 (de) | Methoden zur bestimmung der blutplaettchenfunktion | |
| ATE171372T1 (de) | Verwendung eines antagonisten der substanz p zur behandlung von hautrötungen neurogen ursprungs | |
| DE69606837D1 (de) | Gerät zur Überprüfung der Bestimmungen von klinischen Analysen | |
| DE69733861D1 (de) | Verwendung von neuronalem apoptose-inhibitorprotein | |
| ATE300944T1 (de) | Verwendung von substituierten distamycin- acryloylderivaten zur behandlung von tumoren die mit erhöhten glutathion-spiegeln zusammenhängen | |
| ATE404203T1 (de) | Verwendung von desoxypeganin zur behandlung der klinischen depression | |
| DE60228444D1 (de) | Verfahren zur herstellung von cumylphenol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: AVENTIS HOLDINGS INC., GREENVILLE, DEL., US |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: AVENTISUB II INC., GREENVILLE, DEL., US |